Unlabelled: In this open study, 20 toddlers and 80 schoolchildren received an intramuscular dose of Epaxal and a booster dose 12 mo later to assess the efficacy and safety of this aluminium-free, virosomal hepatitis A vaccine. Four weeks after primary vaccination, 94% of toddlers and 99% of schoolchildren had seroconverted, and all toddlers and 94% of schoolchildren remained seroprotected for 12 mo.
Conclusion: After vaccination with Epaxal and booster, all subjects were seroprotected. Epaxal was very well tolerated by both age groups.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
virosomal hepatitis
8
hepatitis vaccine
8
epaxal booster
8
immunogenicity safety
4
safety virosomal
4
epaxal
4
vaccine epaxal
4
epaxal healthy
4
toddlers
4
healthy toddlers
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!